EMEDvs its industry peers
A metric-by-metric comparison of EMED against SIC 3841 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EMEDThis | — | — | — | — | 17.3%#2 | 23.9%#4 | -153.1%#4 | — | — | 4#1 | — | — |
| BVS | $877M#2 | 16.6x#1 | 3.8x#1 | 1.5x#1 | -0.9%#4 | 162.9%#2 | 9.5%#1 | 10.0%#1 | 12.1%#1 | — | 81.1%#1 | — |
| BWAY | $526M#3 | — | — | 12.8x#2 | 29.0%#1 | 169.6%#1 | 3.4%#2 | — | — | — | — | — |
| DRTS | $1.3B#1 | — | 17.0x#3 | — | — | -34.3%#6 | — | -55.3%#4 | -60.3%#4 | — | — | — |
| DRTSW | $346M#4 | — | 4.5x#2 | — | — | -34.3%#6 | — | -55.3%#4 | -60.3%#4 | — | — | — |
| EBRCZ | — | — | — | — | — | -19.5%#5 | -2850.2%#6 | -70.8%#6 | -89.8%#6 | — | — | — |
| ECIA | — | — | — | — | -0.5%#3 | 68.2%#3 | -2.6%#3 | -11.8%#2 | -7.9%#2 | — | — | — |
| FOFA | — | — | — | — | — | -390.4%#8 | -226.0%#5 | -49.4%#3 | -41.6%#3 | — | — | — |
| GIPL | — | — | — | — | — | -427.4%#9 | — | -135.1%#7 | -245.3%#7 | — | — | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 3841). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. This table timed out mid-build, so it covers part of the group; ranks are within the rows shown and it fills in shortly. Table built 2026-09-16.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice